Evidence map›Paper›PMID 36400777›Full record

ArticleNature communications2022

A Myb enhancer-guided analysis of basophil and mast cell differentiation.

Takayoshi Matsumura, Haruhito Totani, Yoshitaka Gunji, Masahiro Fukuda, Rui Yokomori, Jianwen Deng, Malini Rethnam, Chong Yang, Tze King Tan, Tadayoshi Karasawa and 5 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Takayoshi MatsumuraCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. csitkm@nus.edu.sg.ORCID 0000-0003-3394-9506
Haruhito TotaniCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Yoshitaka GunjiDivision of Inflammation Research, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.ORCID 0000-0003-1721-0939
Masahiro FukudaSignature Program in Neuroscience and Behavioral Disorders, Duke-NUS Medical School, Singapore, Singapore.ORCID 0000-0003-4868-0677
Rui YokomoriCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Jianwen DengCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Malini RethnamCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Chong YangCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Tze King TanCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-1623-615X
Tadayoshi KarasawaDivision of Inflammation Research, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.ORCID 0000-0002-6738-2360
Kazuomi KarioDivision of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Masafumi TakahashiDivision of Inflammation Research, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.ORCID 0000-0003-2716-7532
Motomi OsatoCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.ORCID 0000-0003-3982-9054
Takaomi SandaCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.
Toshio SudaCancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. sudato@keio.jp.ORCID 0000-0001-7540-1771
National University of Singapore · SGJichi Medical University · JPDuke-NUS Medical School · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The transcription factor MYB is a crucial regulator of hematopoietic stem and progenitor cells. However, the nature of lineage-specific enhancer usage of the Myb gene is largely unknown. We identify the Myb -68 enhancer, a regulatory element which marks basophils and mast cells. Using the Myb -68 enhancer activity, we show a population of granulocyte-macrophage progenitors with higher potential to differentiate into basophils and mast cells. Single cell RNA-seq demonstrates the differentiation trajectory is continuous from progenitors to mature basophils in vivo, characterizes bone marrow cells with a gene signature of mast cells, and identifies LILRB4 as a surface marker of basophil maturation. Together, our study leads to a better understanding of how MYB expression is regulated in a lineage-associated manner, and also shows how a combination of lineage-related reporter mice and single-cell transcriptomics can overcome the rarity of target cells and enhance our understanding of gene expression programs that control cell differentiation in vivo.

Indexed as

BasophilsHematopoiesisAnimalsCell DifferentiationLeukocyte CountMiceStem Cells

Identifiers

PMID36400777
PMCPMC9674656
OpenAlexW4309564165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.